Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for Volixibat in Primary biliary cholangitis, Liver disease. The expected timing is based on the latest available company guidance and may change.
VANTAGE PBC trial. 5/9/25- 28wk data reported. 8/6/25- Complete enrollment in 2026. 11/04/25:- Topline data in H1 2027. 11/7/25- Additional analyses presented at AASLD'25. 01/12/26:- VANTAGE PBC Phase 2b enrollment now expected to complete in H2 2026; topline data remains H1 2027. 02/25/26:- VANTAGE Phase 2b in PBC enrollment reiterated to complete H2 2026; topline data still expected H1 2027. 05/04/26:- VANTAGE Ph2b PBC topline data now expected Q1 2027. 05/06/26:- VANTAGE Phase 2b PBC topline results timing reiterated as Q1 2027. 05/30/26:- Volixibat noted as Phase 2b for PBC; FDA Breakthrough Therapy designation highlighted. 08/05/26:- VANTAGE Ph2b PBC enrollment completed; topline results expected Q1 2027.
Verification
Confirm timing and program details against the company announcement or filing.